Impala Healthtech Research Limited In Uganda, 9 out of 10 infections are diagnosed without adequate laboratory investigation, putting treatment decisions on shaky ground. This fuels irrational antimicrobial use and drives the spread of antimicrobial resistance (AMR). During just one month in the ICU of Uganda’s National Referral Hospital, two patients died from infections resistant to all available drugs, while two others died because they couldn’t afford last-line treatments like Polymyxins. AMR is now Uganda’s deadliest infectious threat, killing 30,000 people annually, costing the healthcare system $108 million, and inflicting $500 million in economic losses. We’re rolling out DIGAMS (digamsapp.com)—a smarter diagnostic and treatment support tool to combat AMR. DIGAMS enables under-resourced health facilities to: 1. Access remote advanced diagnostics. 2. Receive AI-driven treatment recommendations. 3. Monitor real-time resistance patterns to inform smarter prescribing. Sectors Biotechnology and medical research, HealthTech Location Kampala, Uganda Stage Sign in to view details Markets Sign in to view details Customer model Sign in to view details Revenue Sign in to view details Contact Sign in to view details Social media